Therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM), and method for treating ham
Patent Information
- Application Number
- MYPI2021000283
- Authority / Receiving Office
- MY · MY
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-07-19
- Filing Date
- 2019-07-19
- Publication Date
- 2025-03-04
- Estimated Expiration
- 2039-07-19
AI Technical Summary
Current treatments for HTLV-1 associated myelopathy (HAM) are ineffective, particularly for advanced nerve destruction cases, and there is a need for a more comprehensive method to manage the disease.
A therapeutic or preventive agent containing an RGMa inhibitor, such as an antibody that recognizes RGMa, is administered to patients with HAM to inhibit RGMa activity or expression, thereby reducing inflammation and neuronal cell death.
The RGMa inhibitor effectively suppresses the production of CXCL10, increases IL-10 production, and inhibits neuronal cell death, providing a therapeutic benefit for HAM patients by reducing inflammatory pathology and promoting tissue repair.
Smart Images

Figure PI2021000283_DRAWING_001 
Figure PI2021000283_DRAWING_002 
Figure PI2021000283_DRAWING_003
Abstract
Description
Therapeutic or prophylactic agent for HTLV-1 associated myelopathy (HAM), and method for treating HAM
[0001] The present invention relates to a therapeutic or prophylactic agent for HTLV-1 associated myelopathy (HAM). The present invention also relates to a method for treating HAM.
[0002] HTLV-1 (Human T-cell Lukemia Virus Type 1) is a virus that infects T cells and the like (mainly CD4-positive T cells), which are one of the white blood cells in the blood. T cells infected with HTLV-1 form chronic inflammation in the spinal cord, resulting in damage and degeneration of spinal nerve cells, and causing spastic spinal paralysis. Spastic spinal paralysis caused by cells infected with HTLV-1 is called HTLV-1 associated myelopathy (also abbreviated as HAM). Symptoms of HAM include symptoms such as paralysis of both legs, pain, urinary disorders, and stubborn constipation due to nerve tissue damage. As these symptoms progress, a wheelchair or bedridden lifestyle becomes necessary. HAM is one of the diseases designated as intractable diseases in Japan. Currently, no effective treatment method for HAM has been established, and only symptomatic treatment is carried out. As one of the treatment methods, it has been proven that a treatment method using an anti-CCR4 antibody can reduce HTLV-1 infected cells, reduce spinal cord inflammation in HAM, and have an effect of improving symptoms (Non-Patent Document 1, Patent Document 5).
[0003] The RGMa protein is a kind of protein RGM (Repulsive guidance molecule) family involved in axon guidance of nerve cells in the retina and hippocampus, closure of the neural tube, etc. The functions of RGM are not limited to these, and it is known to have various functions.
[0004] For example, Patent Document 1 discloses that RGM is expressed in bone marrow-derived dendritic cells (BMDCs), CD4 + T cells and CD11b + macrophages express RGM receptors, and when RGM binds to the RGM receptors, CD4 + T cells and CD11b +It has been disclosed that the cell adhesion activity of macrophages is enhanced. Furthermore, Patent Document 1 discloses that both clinical symptoms and tissue lesions in a multiple sclerosis model mouse can be alleviated by an anti-RGM neutralizing antibody, and that antigen-specific and non-specific T cell activation was attenuated in spleen cells obtained from these mice.
[0005] Patent documents 2 and 3 disclose neutralizing monoclonal antibodies against RGMa that selectively inhibit the binding of RGMa to its receptor neogenin and to bone morphogenetic proteins 2 and 4 (BMP-2 and BMP-4). These neutralizing monoclonal antibodies are said to be able to promote nerve regeneration and regrowth of damaged neuronal connections in the damaged and inflamed human central nervous system, specifically in neurodegenerative diseases such as multiple sclerosis, acute spinal cord injury, post-traumatic brain injury, Huntington's disease, Parkinson's disease, and Alzheimer's disease.
[0006] Patent Document 4 discloses that RGMa is localized in the central nervous system myelin, fresh lesions, and mature scar tissue of humans suffering from traumatic brain injury or ischemic stroke, and discloses a method for detecting and quantifying RGMa fragments for the purpose of diagnosing these neurodegenerative diseases. Furthermore, Patent Document 4 lists the following as target neurodegenerative diseases and disorders for which RGMa fragments should be detected: multiple sclerosis, Parkinson's disease, Alzheimer's disease, Tay-Sachs disease, Niemann-Pick disease, Gaucher disease, Harler syndrome, Huntington's disease, amyotrophic lateral sclerosis, idiopathic inflammatory demyelinating disease, vitamin B12 deficiency, central pontine myelinolysis, spinal cord fistula, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, spinal cord injury, traumatic brain injury, stroke, glaucoma, diabetic retinopathy, age-related macular degeneration, and leukodystrophy.
[0007] International Publication No. 2011 / 071059, Japanese Patent Publication No. 2014-138599, Japanese Patent Publication No. 2016-175897, Japanese Patent Publication No. 2017-526930, Japanese Patent Publication No. 2010-100578
[0008] N Engl J Med, 2018, 378, 529-538.
[0009] While methods using anti-CCR4 antibodies disclosed in Non-Patent Document 1 and Patent Document 5 can improve the symptoms of HAM, the effect of anti-CCR4 antibodies is limited in HAM patients with advanced nerve damage. Therefore, there is a need for a better method that can treat HAM.
[0010] This invention has been made in view of the above-mentioned problems, and aims to provide a therapeutic agent and a therapeutic method that can treat HAM.
[0011] As a result of diligent research to solve the aforementioned problems, the inventors of this invention discovered that substances that inhibit RGMa are effective in treating HAM, and thus completed the present invention.
[0012] In other words, the present invention is as follows: [1] A therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM) comprising an RGMa inhibitor. [2] The therapeutic or prophylactic agent for HAM according to [1], wherein the RGMa inhibitor is an antibody that recognizes RGMa. [3] A method for treating HAM, comprising administering a pharmacologically effective amount of an RGMa inhibitor to a patient with HTLV-1-associated myelopathy (HAM) who requires it. [4] The method for treating HAM according to [3], wherein the RGMa inhibitor is an antibody that recognizes RGMa.
[0013] According to the present invention, HAM, an intractable disease, can be treated.
[0014] This figure shows the classification of CD4-positive T cells into groups P, D, and N based on CADM1, an indicator of HTLV-1 infected cells, and CD7. This figure shows the expression levels of the RGMa gene in normal T cells (Normal.CD4), CD4-positive T cells from HAM patients (HAM.CD4), CD4-positive / CADM1-negative / CD7-positive T cells from healthy individuals (Normal.P), CD4-positive / CADM1-negative / CD7-positive T cells from HTLV-1 infected individuals (P group), CD4-positive / CADM1-positive / CD7-positive T cells from HTLV-1 infected individuals (D group), CD4-positive / CADM1-positive / CD7-negative T cells from HTLV-1 infected individuals (N group), CD4-positive / CADM1-positive / CD7-negative T cells from acute ATL patients (Acute.N), healthy individuals' CD4-positive T cells (Normal.CD4.1), PBMCs from smoldering ATL patients (Smoldering), PBMCs from chronic ATL patients (Chronic), and PBMCs from acute ATL patients (Acute). This figure also shows the expression levels of RGMa in CD4-positive T cells from HAM patients and CD4-positive T cells from healthy individuals. This figure shows the results of analyzing RGMA expression levels across cell types in HAM patient PBMCs. This figure shows the changes in RGMA expression associated with HTLV-1 virus expression in cultured HAM patient PBMCs. This figure shows the H3K27me3 level approximately -2,916 bp upstream from the transcription start site of the RGMA gene. This figure shows the level of RGMA gene mRNA when a lentiviral vector containing cDNA encoding HTLV-1 Tax was introduced into the human CD4-positive T-cell leukemia cell line Jurkat. This figure shows the results of analyzing the protein expression of Tax and RGMA in the HTLV-1-tax expression-inducing cell line JPX-9. This figure shows the results of the effect of RGMA antibodies on spontaneous proliferation activity in HAM patient PBMCs. This figure shows the results of the effect of RGMA antibodies on changes in HTLV-1 proviral load in HAM patient PBMCs. This figure shows the results of the effect of RGMA antibodies on CXCL10 production in HAM patient PBMCs. This figure shows the results of the action of RGMa antibodies on cytokine production in HAM patient PBMCs.This figure shows that HAM-PBMCs induced apoptosis in neuronal cell lines. This figure shows the results of the inhibitory effect of RGMa antibody on apoptosis induction in neuronal cell lines by HTLV-1-tax-inducible cell lines. (a) is a FACS plot when NB-1 cells and JPX-9 cells (unstimulated) are co-cultured. (b) is a FACS plot when NB-1 cells and CdCl2-stimulated JPX-9 cells (HTLV-1-tax-expressing cells) are co-cultured. (c) is a FACS plot when a control antibody is added to the conditions in (b). (d) is a FACS plot when an anti-RGMa antibody is added to the conditions in (b).
[0015] The embodiments of the present invention will be described in detail below. However, the present invention is not limited to the embodiments described below, and can be implemented with various modifications within the scope of its gist.
[0016] The present invention relates to a therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM) comprising an RGMa inhibitor. The RGMa inhibitor may be a substance that acts on RGMa itself to inhibit its activity, or a substance that suppresses the expression of RGMa. Examples of RGMa inhibitors include compounds that have activity to inhibit RGMa, and antibodies that recognize RGMa.
[0017] Furthermore, RGMa inhibitors include, for example, substances that suppress RGMa expression, such as siRNA (short interfering RNA), shRNA (short hairpin RNA), and antisense oligonucleotides of genes that express RGMa. Examples of RGMa genes include, but are not limited to, the human RGMa gene consisting of the nucleotide sequence shown in SEQ ID NO: 1 and the RGMa gene consisting of the nucleotide sequence shown in SEQ ID NO: 2. Information on the nucleotide sequences of RGMa genes from various organisms can be obtained from databases such as GenBank.
[0018] siRNA is a double-stranded RNA that can suppress the expression of the target RGMa gene. The length of the base sequence (base length) of siRNA is not particularly limited, but is preferably less than about 30 bases, more preferably about 19 to 27 bases, and even more preferably about 21 to 25 bases. shRNA refers to a molecule of about 20 base pairs or more that has a double-stranded structure within the molecule by containing a partially palindromic base sequence in single-stranded RNA, and consists of a short hairpin structure with a protrusion at the 3' end. After being introduced into a cell, shRNA is degraded into lengths of about 20 bases within the cell and can suppress the expression of the target RGMa gene in the same way as siRNA.
[0019] siRNA and shRNA can be artificially chemically synthesized. Furthermore, siRNA and shRNA can be synthesized in vitro from template DNA, for example, using T7 RNA polymerase and a T7 promoter, to produce antisense and sense RNA.
[0020] Antisense oligonucleotides can be any nucleotide that is complementary to or hybridizes with a sequence of less than approximately 30 consecutive bases in the DNA sequence of the RGMa gene, and may be either DNA or RNA. They may also be modified as long as it does not impair their function. Antisense oligonucleotides can be synthesized by conventional methods, and can be easily synthesized, for example, using commercially available DNA synthesizers.
[0021] As the RGM inhibitor included in the therapeutic or prophylactic agent for HAM of the present invention, an antibody that recognizes RGMa is preferred. Hereinafter, an antibody that recognizes RGMa will also be referred to as an RGMa antibody. The RGMa antibody in the present invention may be any antibody that binds to RGMa and inhibits its activity, for example, an antibody that, by binding to RGMa, prevents RGMa from binding to the RGMa receptor.
[0022] The RGMa antibody in this invention may be a monoclonal antibody or a polyclonal antibody. Furthermore, the antibody in this invention may be any isotype of IgG, IgM, IgA, IgD, or IgE. The RGMa antibody in this invention may be, for example, a mouse antibody, a human-type CDR-transplanted antibody, a human-type chimeric antibody, a humanized antibody, or a fully human antibody, or it may be a small molecule antibody. These antibodies may be used individually or in combination of two or more.
[0023] Humanized CDR-transplanted antibodies are antibodies in which the CDR of an antibody from a non-human animal has been replaced with the CDR of a human antibody. Humanized chimeric antibodies are antibodies consisting of a variable region derived from an antibody from a non-human animal and a constant region derived from a human antibody. Furthermore, humanized antibodies refer to antibodies from non-human animals in which a portion derived from a human antibody has been incorporated while retaining a portion with high safety. This concept includes humanized chimeric antibodies and humanized CDR-transplanted antibodies.
[0024] In this specification, "small molecule antibody" means an antibody fragment or an antibody fragment to which any molecule has been conjugated, and which recognizes the same epitope as the original antibody. Specifically, this includes, but is not limited to, Fab consisting of VL, VH, CL, and CH1 regions; F(ab')2 in which two Fabs are linked by a disulfide bond at a hinge region; Fv consisting of VL and VH; scFv, a single-chain antibody in which VL and VH are linked by an artificial polypeptide linker; as well as sdFv, Diabody, and sc(Fv)2.
[0025] The RGMa antibody used in this invention can be prepared by known methods using RGMa or a fragment thereof as an immunogen. The fact that the obtained antibody is an RGMa antibody can be confirmed by its RGMa activity. Examples of RGMa include human RGMa containing the amino acid sequence shown in SEQ ID NO: 3, and RGMa containing the amino acid sequence shown in SEQ ID NO: 4. Various biological sources of RGMa can be used as immunogens. The amino acid sequences of RGMa can be obtained from known databases such as the Protein Data Bank.
[0026] When the RGMa antibody used in the present invention is a polyclonal antibody, it can be produced, for example, as follows. First, RGMa or fragments thereof are dissolved in phosphate-buffered saline (also referred to as PBS) as an antigen, and an appropriate amount of a conventional adjuvant, such as Freund's complete adjuvant, is mixed in as needed. Mammals such as mice, rats, rabbits, goats, and horses are immunized with this mixture as an immunogen. The immunization method is not particularly limited, but examples include subcutaneous injection or intraperitoneal injection once or twice or more at appropriate intervals. Next, blood is collected from the immunized animals according to a conventional method, serum is separated, and the polyclonal antibody fraction can be obtained by purification. When the RGMa antibody used in the present invention is a monoclonal antibody, the monoclonal antibody can be obtained by fusing immune cells obtained from the above-immunized mammals, such as splenocytes and myeloma cells, to obtain a hybridoma, and then collecting the antibody from the culture of the hybridoma. Furthermore, the above monoclonal antibodies can also be produced by cloning the antibody gene from a hybridoma, incorporating it into a suitable vector, introducing it into host cells, and using genetic recombination technology to produce recombinant monoclonal antibodies. In addition, the above monoclonal antibodies can also be produced using phage display.
[0027] As the RGMa antibody used in the present invention, for example, antibodies disclosed in Yamashita, T., Mueller, BK & Hata, K. Neogenin and repulsive guidance molecule signaling in the central nervous system. Curr. Opin. Neurobiol. 17, 29-34 (2007); JP 2014-138599 A; JP 2016-175897 A; JP 2017-526930 A; International Publication No. 2016 / 175236; JP 2015-508061 A can be used. In addition, as the RGMa antibody used in the present invention, for example, it can be obtained as a commercially available product from companies such as Immunobiological Laboratories, Inc. (IBL) and R&D Systems.
[0028] The RGMa antibody preferably contains at least one CDR as its antigen-binding domain, which includes an amino acid sequence selected from the group consisting of GTTPDY (SEQ ID NO: 7); FQATHDPLT (SEQ ID NO: 10); ARRNEYYGSSFFDY (SEQ ID NO: 13); LQGYIPPRT (SEQ ID NO: 16); and a modified CDR amino acid sequence having at least 50% sequence identity with one of the aforementioned sequences. The above sequence identity is preferably 80% or more, and more preferably 90% or more. In this specification, amino acids may be shown using conventional single-letter or three-letter notation.
[0029] The complementarity-determining region (CDR) is the region within the variable region of an immunoglobulin molecule that forms the antigen-binding site. Also known as the hypervariable region, it refers to the part of the immunoglobulin molecule where the amino acid sequence changes particularly significantly. There are three CDRs in both the light chain and the heavy chain (CDR-L1, CDR-L2, CDR-L3, and CDR-H1, CDR-H2, CDR-H3). In this application, the CDR of an immunoglobulin molecule is determined according to Kabat's numbering system (Kabat et al., 1987, Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA). Furthermore, in the antibody defined by the amino acid sequences of the light and heavy chains in this invention, the amino acid sequence of the CDR is invariant from a predetermined sequence, while other parts may change due to mutations, etc. When there are mutations, etc., in parts other than the CDR, homology of 90% or more is preferable.
[0030] Furthermore, it is preferable that the RGMa antibody further contains at least one CDR containing an amino acid sequence selected from the group consisting of SEQ ID NOs. 5, 6, 8, 9, 11, 12, 14, 15 and modified CDR amino acid sequences having at least 50% sequence identity with one of the sequences. The above sequence identity is preferably 80% or more, and more preferably 90% or more.
[0031] The RGMa antibody more preferably contains at least three CDRs selected from the variable domain CDR sets shown in Table 1, or from a variable domain set in which at least one of the three CDRs is a modified CDR amino acid sequence having at least 50%, preferably 80%, and more preferably 90% sequence identity with the parent sequence. Furthermore, the RGMa antibody is even more preferably to contain at least two of the variable domain CDR sets shown in Table 1. Moreover, the at least two variable domain CDR sets are preferably a combination of the VH5F9 set and the VL5F9 set, or a combination of the VH8D1 set and the VL8D1 set.
[0032]
[0033] The RGMa antibody may include a framework region. Examples of amino acid sequences included in the framework region include SEQ ID NOs: 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, and 40. These amino acid sequences may be a single sequence or a combination of two or more sequences. Furthermore, it is preferable that the RGMa antibody includes, as heavy chain variable domains and light chain variable domains, at least one heavy chain variable domain selected from SEQ ID NOs: 41, 42, 43, 44, 45, 46, 47, 48, and 49; and / or at least one light chain variable domain selected from SEQ ID NOs: 50, 51, and 52.
[0034] Furthermore, while the binding site of an RGMa antibody to RGMa is not particularly limited as long as it is a site that causes RGMa inhibition, for example, in the case of human RGMa, it is preferable to bind to one or more peptides having the amino acid sequence represented by EEVVNAVEDWDSQG (SEQ ID NO: 53), NQQIDFQAFHTNAE (SEQ ID NO: 54), PTAPETFPYET (SEQ ID NO: 55), KLPVEDLYYQA (SEQ ID NO: 56), and LYERTRDLPGRAAAGL (SEQ ID NO: 57). It is more preferable for the RGMa antibody to bind to a peptide having the amino acid sequence represented by SEQ ID NO: 53 and / or SEQ ID NO: 54, and more preferably to bind to a peptide having the amino acid sequence represented by SEQ ID NO: 53 and / or SEQ ID NO: 54 and a peptide having the amino acid sequence represented by SEQ ID NO: 55 and / or SEQ ID NO: 56. It is preferable for the RGMa antibody to be an antibody that binds to the 250th amino acid position or later in the amino acid sequence of human RGMa. It is more preferable for the RGMa antibody to bind to a peptide having the amino acid sequence represented by SEQ ID NO: 53 and SEQ ID NO: 54, and SEQ ID NO: 55 or SEQ ID NO: 56.
[0035] RGMa antibodies may be polyclonal antibodies and monoclonal antibodies obtained by immunizing mammals such as mice with the RGMa protein or a partial fragment thereof (for example, a fragment containing one or more of SEQ ID NOs. 53 to 57) as an antigen, chimeric antibodies and humanized antibodies produced using genetic recombination technology, and human antibodies produced using human antibody-producing transgenic animals, etc. In the present invention, when the RGMa antibody is administered to humans as a pharmaceutical, humanized antibodies or human antibodies are preferred from the viewpoint of side effects. The RGMa antibody may be used as a partial fragment of a polyclonal antibody and / or monoclonal antibody that recognizes the RGMa protein or a partial fragment thereof (for example, a fragment containing one or more of SEQ ID NOs. 53 to 57) as an antigen, or it may be a low molecular weight antibody.
[0036] In addition to those shown in Table 1, RGMa antibodies may include those in which the amino acid sequences of the light chain complementarity region 1 (LCDR1), light chain complementarity region 2 (LCDR2), light chain complementarity region 3 (LCDR3), heavy chain complementarity region 1 (HCDR1), heavy chain complementarity region 2 (HCDR2), and heavy chain complementarity region 3 (HCDR3) are as follows: LCDR1:RASQDISSYLN (SEQ ID NO: 58), LCDR2:YTSRLHS (SEQ ID NO: 59), LCDR3:QQLNTLP (SEQ ID NO: 60), HCDR1:DAWMD (SEQ ID NO: 61), HCDR2:EIRSKANNHATYYAESVKG (SEQ ID NO: 62), and HCDR3:RDGAY (SEQ ID NO: 63), or LCDR1:RSSQSLVHSNGNTYLH (SEQ ID NO: 64), LCDR2:KVSNRFS (SEQ ID NO: 65). The isolated RGMa antibody, or its antigen-binding fragment, may contain LCDR3:SQSTHVP (SEQ ID NO: 66), HCDR1:TSYYWN (SEQ ID NO: 67), HCDR2:YISYDGTNNYNPSLKN (SEQ ID NO: 68), and HCDR3:SFG. Each CDR sequence may contain one or more amino acids substituted, deleted, and / or added; for example, one or two amino acids may be substituted, deleted, and / or added.
[0037] Examples of the RGMa antibody include an antibody having the amino acid sequence of SEQ ID NO: 73 in the light chain and the amino acid sequence of SEQ ID NO: 74 in the heavy chain. In the amino acid sequences represented by these SEQ ID NOs, there may be substitution, deletion, addition or insertion of one or several amino acids (1 to 20, 1 to 10 or 1 to 5). Such substitution, deletion or addition may be introduced into the CDR, but is preferably introduced into regions other than the CDR.
[0038] A mouse / human chimeric antibody having a human-derived constant region may also be used. Examples of the mouse / human chimeric antibody include an antibody having the amino acid sequence of SEQ ID NO: 77 (variable region: 1 to 107) in the light chain and the amino acid sequence of SEQ ID NO: 78 (variable region: 1 to 116) in the heavy chain. In the amino acid sequences represented by these SEQ ID NOs, there may be substitution, deletion, addition or insertion of one or several amino acids (1 to 20, 1 to 10 or 1 to 5). Such substitution, deletion or addition may be introduced into the CDR, but is preferably introduced into regions other than the CDR.
[0039] A humanized antibody having a human-derived region other than the CDR may also be used. Examples of the humanized antibody include an antibody having any one of the amino acid sequences of SEQ ID NOs: from 70 to 87 (variable region: up to 116 residues on the N-terminal side) in the heavy chain and any one of the amino acid sequences of SEQ ID NOs: from 88 to 94 (variable region: up to 1 to 107 residues on the N-terminal side) in the light chain. In the amino acid sequences represented by these SEQ ID NOs, there may be substitution, deletion, addition or insertion of one or several amino acids (1 to 20, 1 to 10 or 1 to 5). Such substitution, deletion or addition may be introduced into the CDR, but is preferably introduced into regions other than the CDR.
[0040] The heavy chain amino acid sequence and the light chain amino acid sequence may be any combination of these, but preferably an antibody having the amino acid sequence of SEQ ID NO: 84 in the heavy chain and the amino acid sequence of SEQ ID NO: 88 in the light chain. Among the amino acid sequence of SEQ ID NO: 84, the amino acid sequence corresponding to the heavy chain variable region is represented by SEQ ID NO: 95, and the amino acid sequence corresponding to the light chain variable region is represented by SEQ ID NO: 96.
[0041] Preferably, the RGMa antibody is an isolated RGMa antibody or its antigen-binding fragment, wherein the heavy chain variable region (VH) contains EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAEIRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRDGAYWGKGTTVTVSS (SEQ ID NO: 95) or an amino acid sequence with at least 90% identity to the said amino acid sequence, and the light chain variable region (VL) contains DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGGTKVEME (SEQ ID NO: 96) or an amino acid sequence with at least 90% identity to the said amino acid sequence.
[0042] Examples of RGMa antibodies include antibodies having the amino acid sequence of SEQ ID NO: 75 in the light chain and the amino acid sequence of SEQ ID NO: 76 in the heavy chain. In the amino acid sequences represented by these SEQ ID NOs, one or more amino acids (1 to 20, 1 to 10, or 1 to 5) may be substituted, deleted, added, or inserted. Such substitutions, deletions, or additions may be introduced into the CDR, but it is preferable that they be introduced into a region other than the CDR. The constant region may be derived from humans, resulting in a mouse / human chimeric antibody, or the region other than the CDR may be derived from humans, resulting in a humanized antibody.
[0043] Furthermore, the anti-RGMa antibody may be an isolated RGMa antibody or an antigen-binding fragment thereof, selected from (a1) to (h1) below. (a1) An anti-RGMa antibody or an antigen-binding fragment thereof, comprising a light chain variable region comprising LCDR1 containing the amino acid sequence described in SEQ ID NO: 97, LCDR2 containing the amino acid sequence described in SEQ ID NO: 98, and LCDR3 containing the amino acid sequence described in SEQ ID NO: 99, and a heavy chain variable region comprising HCDR1 containing the amino acid sequence described in SEQ ID NO: 100, HCDR2 containing the amino acid sequence described in SEQ ID NO: 101, and HCDR3 containing the amino acid sequence described in SEQ ID NO: 102. (b1) An anti-RGMa antibody or an antigen-binding fragment thereof, comprising a light chain variable region comprising LCDR1 containing the amino acid sequence described in SEQ ID NO: 97, LCDR2 containing the amino acid sequence described in SEQ ID NO: 98, and LCDR3 containing the amino acid sequence described in SEQ ID NO: 103, and a heavy chain variable region comprising HCDR1 containing the amino acid sequence described in SEQ ID NO: 100, HCDR2 containing the amino acid sequence described in SEQ ID NO: 101, and HCDR3 containing the amino acid sequence described in SEQ ID NO: 102. (c1) An anti-RGMa antibody or its antigen-binding fragment, comprising a light chain variable region comprising LCDR1 containing the amino acid sequence described in SEQ ID NO: 97, LCDR2 containing the amino acid sequence described in SEQ ID NO: 98, and LCDR3 containing the amino acid sequence described in SEQ ID NO: 104, and a heavy chain variable region comprising HCDR1 containing the amino acid sequence described in SEQ ID NO: 100, HCDR2 containing the amino acid sequence described in SEQ ID NO: 101, and HCDR3 containing the amino acid sequence described in SEQ ID NO: 102. (d1) An anti-RGMa antibody or its antigen-binding fragment, comprising a light chain variable region comprising LCDR1 containing the amino acid sequence described in SEQ ID NO: 97, LCDR2 containing the amino acid sequence described in SEQ ID NO: 98, and LCDR3 containing the amino acid sequence described in SEQ ID NO: 105, and a heavy chain variable region comprising HCDR1 containing the amino acid sequence described in SEQ ID NO: 100, HCDR2 containing the amino acid sequence described in SEQ ID NO: 101, and HCDR3 containing the amino acid sequence described in SEQ ID NO: 102.An anti-RGMa antibody comprising a light chain variable region comprising LCDR1 containing the amino acid sequence set forth in SEQ ID NO: 97, LCDR2 containing the amino acid sequence set forth in SEQ ID NO: 98, and LCDR3 containing the amino acid sequence set forth in SEQ ID NO: 106, and a heavy chain variable region comprising HCDR1 containing the amino acid sequence set forth in SEQ ID NO: 100, HCDR2 containing the amino acid sequence set forth in SEQ ID NO: 101, and HCDR3 containing the amino acid sequence set forth in SEQ ID NO: 102, or an antigen-binding fragment thereof; (f1) an anti-RGMa antibody comprising a light chain variable region comprising LCDR! containing the amino acid sequence set forth in SEQ ID NO: 97, LCDR2 containing the amino acid sequence set forth in SEQ ID NO: 98, and LCDR3 containing the amino acid sequence set forth in SEQ ID NO: 107, and a heavy chain variable region comprising HCDR1 containing the amino acid sequence set forth in SEQ ID NO: 100, HCDR2 containing the amino acid sequence set forth in SEQ ID NO: 101, and HCDR3 containing the amino acid sequence set forth in SEQ ID NO: 1!02, or an antigen-binding fragment thereof; (g1) an anti-RGMa antibody comprising a light chain variable region comprising LCDR1 containing the amino acid sequence set forth in SEQ ID NO: 97, LCDR2 containing the amino acid sequence set forth in SEQ ID NO: 98, and LCDR3 containing the amino acid sequence set forth in SEQ ID NO: 108, and a heavy chain variable region comprising HCDR1 containing the amino acid sequence set forth in SEQ ID NO: 100, HCDR2 containing the amino acid sequence set forth in SEQ ID NO: 101, and HCDR3 containing the amino acid sequence set forth in SEQ ID NO: 102, or an antigen-binding fragment thereof; and (h1) an anti-RGMa antibody comprising a light chain variable region comprising LCDR1 containing the amino acid sequence set forth in SEQ ID NO: 97, LCDR2 containing the amino acid sequence set forth in SEQ ID NO: 98, and LCDR3 containing the amino acid sequence set forth in SEQ ID NO: 109, and a heavy chain variable region comprising HCDR1 containing the amino acid sequence set forth in SEQ ID NO: 100, HCDR2 containing the amino acid sequence set forth in SEQ ID NO: 101, and HCDR3 containing the amino acid sequence set forth in SEQ ID NO: 102, or an antigen-binding fragment thereof.
[0044] The RGMa antibody is an antibody having the above-described amino acid sequence, preferably a humanized antibody, and preferably having a constant region of human IgG.
[0045] The RGMa inhibitors in this invention can treat or prevent HAM. As shown in the examples described below and in Figure 13, in HAM patients, neuronal cell death, i.e., spinal cord tissue damage and degeneration, is induced by cells derived from HAM patients. As a result of our investigation, as shown in the examples described below, RGMa is significantly expressed in CD4-positive T cells, which are the main HTLV-1 infected cells in HAM patients, and it was found that RGMa expression is involved in HAM. Furthermore, as a result of tests in which RGMa was inhibited using an RGMa antibody, it was found that RGMa is involved in the production of CXCL10, IL-2, and IL-10. CXCL10 is a protein produced by HAM-pathogenic HTLV-1 infected T cells in response to IFN-γ and is known to induce the pathogenesis of HAM (Brain 2013), and is also known to correlate strongly with the rate of progression of HAM symptoms (PLoS Negl Trop Dis 2013). When RGMa antibodies were applied to cells of HAM patients, the production of CXCL10 was suppressed. Furthermore, IL-10 is a cytokine that works to suppress inflammation. When RGMa antibodies were applied to cells from HAM patients, IL-10 production increased significantly. To bring about a true therapeutic effect on HAM, it is necessary to suppress nerve cell damage. HTLV-1-tax expression levels are high in HTLV-1 infected cells from HAM patients (Blood 2002), and it has been shown that HTLV-1-tax is important in pathogenesis (J Clin Invest 2014). In this invention, it was shown that HTLV-1-tax induces RGMa expression, and that HAM patient-derived cells with high RGMa expression levels induce nerve cell death. Importantly, it was shown that RGMa inhibitors suppress nerve cell death caused by HTLV-1-tax expressing cells. As described above, RGMa inhibitors can suppress the induction of inflammatory pathogenesis in HAM and suppress the inflammatory response by HAM patient cells, thus enabling the treatment or prevention of HAM. Furthermore, RGMa inhibitors not only suppress the inflammatory response specific to HAM, but can also suppress neuronal cell death caused by HTLV-1-tax expressing cells, which are pathogenic cells in HAM patients, thus enabling the treatment or prevention of HAM.
[0046] As described above, RGMa inhibitors can treat or prevent HAM, and the present invention provides: RGMa inhibitors for use in the treatment of HAM; pharmaceutical compositions for use in the treatment of HAM; the use of RGMa inhibitors for the treatment of HAM; the use of RGMa inhibitors in the manufacture of pharmaceuticals for the treatment of HAM; RGMa inhibitors for use in the manufacture of pharmaceuticals for the treatment of HAM; and a method for treating or preventing HAM, comprising administering an effective amount of RGMa inhibitor to a subject in need.
[0047] The therapeutic or prophylactic agent for HAM of the present invention comprises an RGMa inhibitor and may be formulated by further appropriately adding pharmaceutically acceptable carriers and / or additives. Examples of formulations include oral preparations such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, and emulsions; and parenteral preparations such as injections, infusions, suppositories, ointments, and patches. The proportion of carriers or additives should be appropriately determined based on the range commonly used in the pharmaceutical field. Examples of carriers are not particularly limited, but include water, physiological saline, other aqueous solvents, and aqueous or oily bases. Examples of additives are not particularly limited, but include excipients, binders, pH adjusters, disintegrants, absorption enhancers, lubricants, colorants, flavoring agents, and fragrances.
[0048] When the RGMa inhibitor in the present invention is an antibody that recognizes RGMa, it is preferable to administer the antibody, formulated with a pharmaceutically acceptable carrier, as an injectable preparation or infusion, via parenteral administration routes, such as intravenously, intramuscularly, intracutaneously, intraperitoneally, subcutaneously, or locally. The injectable preparation or infusion containing the RGMa antibody can be used as a solution, suspension, or emulsion. As solvents, for example, distilled water for injection, physiological saline, glucose solution, and isotonic solutions (for example, solutions of sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, propylene glycol, etc.) can be used. These solvents may be used individually or in combination of two or more.
[0049] Furthermore, the above-mentioned injectable or intravenous solution may contain additives such as stabilizers, solubilizers, suspending agents, emulsifiers, analgesics, buffers, preservatives, antiseptics, and pH adjusters. Examples of stabilizers include albumin, globulin, gelatin, mannitol, glucose, dextran, ethylene glycol, propylene glycol, ascorbic acid, sodium bisulfite, sodium thiosulfate, sodium EDTA, sodium citrate, and dibutylhydroxytoluene. Examples of solubilizers include alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, polyethylene glycol), and nonionic surfactants (e.g., polysorbate 80®, HCO-50). Examples of suspending agents include glyceryl monostearate, aluminum monostearate, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, and sodium lauryl sulfate. Examples of emulsifiers include gum arabic, sodium alginate, and tragacanth. Examples of pain-relieving agents include benzyl alcohol, chlorobutanol, and sorbitol. Examples of buffering agents include phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, and Tris buffer. Examples of preservatives include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, benzalkonium chloride, sodium dehydroacetate, sodium edetate, boric acid, and borax. Examples of antiseptics include benzalkonium chloride, parahydroxybenzoic acid, and chlorobutanol. Examples of pH adjusters include hydrochloric acid, sodium hydroxide, phosphoric acid, and acetic acid.
[0050] When the RGMa inhibitor in the present invention is a substance that suppresses the expression of RGMa, such as siRNA (short interfering RNA), shRNA (short hairpin RNA), and antisense oligonucleotides of genes that express RGMa, it can be administered in the form of a non-viral vector or a viral vector. When the RGMa inhibitor is in the form of a non-viral vector, methods of administration include introducing nucleic acid molecules using liposomes (liposome method, HVJ-liposome method, cationic liposome method, lipofection method, lipofectamine method, etc.), microinjection, and transferring nucleic acid molecules into cells together with a carrier (metal particles) using a gene gun. When siRNA or shRNA is administered to a living organism using a viral vector, viral vectors such as recombinant adenoviruses and retroviruses can be used. By introducing DNA expressing siRNA or shRNA into detoxified retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, vaccinia viruses, poxviruses, polioviruses, Sindbisviruses, Sendai viruses, SV40, and other DNA or RNA viruses, and then infecting cells or tissues with this recombinant virus, genes can be introduced into cells or tissues.
[0051] The formulations thus obtained can prevent or treat HAM by administering an effective dose to, for example, humans, as well as other mammals such as rats, mice, rabbits, sheep, pigs, cattle, cattle, dogs, and monkeys. The dosage is determined appropriately, taking into consideration the purpose, the severity of the disease, the patient's age, weight, sex, medical history, and the type of active ingredient.
[0052] [Example 1: Comprehensive comparative analysis to elucidate the pathogenesis and pathophysiology of HAM and adult T-cell leukemia / lymphoma (ALT)] As shown in Figure 1, for samples from HTLV-1 infected individuals who had not yet developed symptoms, mRNA expression analysis was performed on CD4-positive cells, specifically for CADM1, an indicator of HTLV-1 infected cells, and for groups P, D, and N classified by CD7. For HAM, CD4-positive and CD4-negative cells enriched with magnetic beads were also analyzed from four peripheral blood mononuclear cells of HAM patients. Similar isolation was performed for healthy individuals (Normal) who were not infected with HTLV-1. Peripheral blood mononuclear cells are also referred to as PBMCs. For ATL (smodering, chronic, and acute disease types), PBMCs consisting mainly of CD4-positive cells were used. Agilent Technologies, Inc.'s monochromatic microarray gene expression analysis was performed.
[0053] A comprehensive comparative analysis of neuronal molecules revealed that RGMa is significantly expressed in CD4-positive cells of HAM patients. 4 cases of normal T cells (Normal.CD4), 4 cases of CD4-positive T cells from HAM patients (HAM.CD4), 3 cases of CD4-positive / CADM1-negative / CD7-positive T cells from healthy subjects (Normal.P), 5 cases of CD4-positive / CADM1-negative / CD7-positive T cells from HTLV-1 infected persons (P group), CD4-positive / CADM1-positive / CD7-positive T cells from HTLV-1 infected persons 5 cases (Group D), HTLV-1 infected CD4 positive / CADM1 positive / CD7 negative T cells 5 cases (N group), acute ATL patient CD4 positive / CADM1 positive / CD7 negative T cells 3 cases (Acute.N), healthy human CD4 positive T cells 21 cases (Normal.CD4.1), 3 cases PBMC from smoldering ATL patients (Smoldering), PBMC from chronic ATL patients 20 cases (Chronic), PBMC from acute ATL patients For 26 cases (Acute), all gene expression data was obtained using Agilent Technologies, Inc.'s Human Gene Expression 4x44K Microarray. After standardization by the median, RGMa gene levels were graphed. The graph plots the Log2 values of the array's fluorescence intensity. CD4-positive T cells derived from HAM patients showed significantly elevated levels compared to all other groups (P < 0.05). The graph is shown in Figure 2.
[0054] [Example 2: Gene Expression Assay in CD4-Positive HAM Patients] CD4-positive T cells were isolated from PBMCs (Peripheral Blood Microorganisms) isolated from the peripheral blood of five HAM patients using a human CD4+ isolation kit (Miltenyi Biotec), and a cell population containing a large number of HTLV-1 infected cells was prepared. Similarly, CD4-positive T cells were isolated from PBMCs of four healthy individuals and used as the control group. Total RNA was recovered from the isolated CD4-positive T cells, and cDNA was prepared using ReverTra Ace (Toyobo). The difference in RGMa expression levels between CD4-positive T cells from HAM patients and CD4-positive T cells from healthy individuals was analyzed by real-time PCR using the prepared cDNA. 18srRNA was used as the internal control. The graph of the analysis results is shown in Figure 3. In the graph, HD-CD4+ refers to the control group, and HAM-CD4+ refers to the group of HAM patients.
[0055] [Example 3: Analysis of RGMa-expressing cells in PBMCs] After Fc block treatment of PBMCs from HAM patients using Clear Back (MBL), anti-CD3-PECy7 (TONBO), CD4-FITC (eBioscience), and CD14-PE (eBioscience) antibodies were added and stained at 4°C for 30 minutes. After washing the antibody-stained PBMCs, FACS sorting was performed using AriaIIIu (BD), and CD3-positive CD4-negative cells (CD3+CD4-), CD3-positive CD4-positive cells (CD3+CD4+), CD3-negative CD14-negative cells (CD3-CD14-), and CD3-negative CD14-positive cells (CD3-CD14+) were separated and collected. Total RNA was collected from each of the collected cells, and cDNA was constructed using ReverTra Ace (Toyobo). The differences in RGMa expression levels between cell types were analyzed using the constructed cDNA by Real-time PCR. 18s rRNA was used as an internal control. The graph of the analysis results is shown in Figure 4. In HAM-PBMCs, it was found that RGMa expression was highest in CD3-positive CD4-positive cells (CD3+CD4+) where infected cells were abundant.
[0056] [Example 4: Changes in RGMa expression associated with culture of HAM patient PBMCs] PBMCs from two HAM patients were suspended in culture medium (RPMI1640 medium (wako) containing 10% FBS (GIBCO)), seeded in 10 wells of a 96-well round bottom plate with 1e5 cells each, and then cultured for 1, 3, 5, and 7 days. Total RNA was extracted from PBMCs cultured for each period, along with PBMCs cultured on Day 0 (when no culture was performed), and cDNA was produced using ReverTra Ace (Toyobo). It is known that HAM patient PBMCs overexpress HTLV-1 virus when cultured, and the changes in RGMa expression associated with culture of HAM patient PBMCs, i.e., associated with viral expression, were analyzed by Real-time PCR using the produced cDNA. 18s rRNA was used as an internal control. The graph showing the results of the analysis is shown in Figure 5.
[0057] [Example 5: Analysis of H3K27me3 levels on all promoters] H3K27me3 levels on all promoters were obtained from 3 normal T cells, 4 CD4-positive T cells from HAM patients (HAM), and 3 PBMCs from acute ATL patients (ATL) using Agilent Technologies' SurePrint G3 Human Promoter 2x400K Microarray. After standardization, the H3K27me3 level approximately -2,916 bp upstream from the transcription start site of the RGMa gene was graphed. The graph is shown in Figure 6. The graph plots the Log2 value of the fluorescence intensity of the array. In the figure, HAM50 and HAM123 refer to HAM patients from whom CD4-positive T cells were obtained, respectively. It was suggested that the repression of RGMa gene expression was released in CD4-positive T cells derived from HAM patients.
[0058] [Example 6: Quantification of RGMa gene mRNA levels] A lentiviral vector containing cDNA encoding HTLV-1 Tax was introduced into the human CD4-positive T-cell leukemia cell line Jurkat, and the levels of RGMa gene mRNA were measured quantitatively by RT-PCR over three days after introduction. RPL19 gene mRNA was also measured and used as an internal standard. A graph showing the quantification results is shown in Figure 7. This suggests that RGMa expression is induced by the HTLV-1 virus.
[0059] [Example 7: Tax-dependent induction of RGMa expression in HTLV-1-tax-inducible cell line JPX-9 cells] JPX9 cells were cultured in medium (RPMI1640 medium containing 10% FBS) for 24 hours, and cadmium chloride (CdCl2; Nacalai Tesque), which induces HTLV-1-tax expression, was added to a final concentration of 20 μM. The cells were then cultured for 1, 2, and 3 days. FACS analysis was performed on the protein expression of Tax and RGMa in both cadmium-treated and untreated JPX9 cells. Both cadmium-treated and untreated JPX9 cells were washed and treated with Foxp3 / Transcription Factor Staining Buffer Kit (eBioscience) for cell permeabilization. Subsequently, anti-Tax-FITC antibody (Lt-4: provided by Professor Tanaka of the University of the Ryukyus) was added and the cells were treated at 4°C for 1 hour to stain the Tax protein expressed in the cells. The stained Tax protein was detected by FACS analysis using CantoII. Cadmium-treated and untreated JPX9 cells were washed, and anti-RGMa antibody (IMBRA, Inc.) was added and treated at 4°C for 30 minutes. The cells were then washed again, and anti-mouse IgG-PE antibody (BioLegend) was added and reacted at 4°C for 30 minutes to stain the RGMa protein expressed in JPX9. The stained RGMa protein was detected by FACS analysis using CantoII. Figure 8 shows the results of the analysis of Tax and RGMa protein expression.
[0060] [Example 8: Investigation of the effect of RGMa antibody on PBMCs from HAM patients] (Effect of RGMa antibody on spontaneous proliferation activity) Four PBMCs from HAM patients were suspended in culture medium (RPMI1640 medium containing 10% FBS), seeded 1e5 cells each in a 96-well round bottom plate, and RGMa antibody (manufactured by R&D Systems) was added to a final concentration of 10 μg / ml. The cells were cultured in a total of 0.1 ml of culture medium at 37°C under 5% CO2 conditions for 7 days. A control group was used, consisting of a group with no additives (Medium), a group with the same concentration of Normal Goat IgG (Santa Cruz Biotechnology) added (Normal IgG), and a group with 1 μg / ml prednisolone (PSL) (Funakoshi) added. Six days after the start of culture, 1 μg Ci was added to each well. 3 H-Thymidine was added, and the cells were cultured at 37°C under 5% CO2 conditions for 16 hours. Subsequently, the cultured cells were adsorbed onto a glass filter (Printed Filtermat A PerkinElmer) using a cell harvester (Tomtec MH3 PerkinElmer), dried, and then impregnated with solid scintillator Meltilex-A (PerkinElmer). The cells were then taken up using MicroBeta (WALLAC MicroBeta TriLux 1450-021). 3 The amount of H-Thymidine was measured in the Medium group of PBMCs in each HAM patient. 3 The average H-Thymidine count was set to 100%, and the relative values for each group were calculated for four HAM patients. 3 The average H-thymidine uptake rate was calculated. The results are shown in Figure 9.
[0061] (Effect of RGMa antibody on changes in HTLV-1 proviral load) PBMCs from four HAM patients were suspended in culture medium (RPMI1640 medium containing 10% FBS), seeded in 96-well round bottom plates with 1 e5 cells each, and RGMa antibody (R&D Systems) was added to a final concentration of 10 μg / ml. The cells were cultured in a total of 0.1 ml of culture medium at 37°C under 5% CO2 conditions for 7 days. Control groups included a group with no additives (Medium), a group with the same concentration of Normal Goat IgG (Santa Cruz Biotechnology) (Normal IgG), and a group with 1 μg / ml prednisolone (PSL) (Funakoshi). Seven days after the start of culture, genomic DNA was extracted from the cell aggregates after centrifugation and removal of the supernatant. The HTLV-1 proviral load (infected cell rate) was measured using the extracted genomic DNA by real-time PCR. The HTLV-1 proviral load in the Medium group of each HAM patient's PBMC was set to 100%, and the relative value of the HTLV-1 proviral load in each group was calculated. The average value of the HTLV-1 proviral load for four HAM patients was then determined. The results are shown in Figure 10.
[0062] (Effect of RGMa antibody on CXCL10 production) To analyze the effect of RGMa antibody on CXCL10 production from PBMCs of HAM patients, PBMCs from four HAM patients were suspended in culture medium (RPMI1640 medium containing 10% FBS), seeded in 96-well round bottom plates with 1 e5 cells each, and RGMa antibody (manufactured by R&D Systems) was added to a final concentration of 10 μg / ml. The cells were cultured in a total of 0.1 ml of culture medium at 37°C under 5% CO2 conditions for 7 days. Control groups included a group with no additives (Medium), a group with the same concentration of Normal Goat IgG (Santa Cruz Biotechnology) (Normal IgG), and a group with 1 μg / ml prednisolone (PSL) (Funakoshi). Seven days after the start of culture, the culture medium was centrifuged and only the culture supernatant was collected. The CXCL10 concentration in the culture supernatant was measured using a Cytokine Beads Array kit (BD Biosciences) and a flow cytometer FACSCantoII (BD Biosciences). The relative CXCL10 concentration in the culture medium of the Medium group was set as 100%, and the average CXCL10 concentration in the culture medium of each group was calculated. The average CXCL10 concentration for four HAM patients was then determined. The results are shown in Figure 11.
[0063] (Effect of RGMa antibody on cytokine production in HAM patient PBMCs) To analyze the effect of RGMa antibody on the production of various cytokines in HAM patient PBMCs, four HAM patient PBMCs were suspended in culture medium (RPMI1640 medium containing 10% FBS), seeded 1e5 cells per 98-well round bottom plate, and RGMa antibody (manufactured by R&D Systems) was added to a final concentration of 10 μg / ml. The cells were cultured in a total of 0.1 ml of culture medium at 37°C under 5% CO2 conditions for 7 days. Control groups included a group with no additives (Medium), a group with the same concentration of Normal Goat IgG (Santa Cruz Biotechnology) (Normal IgG), and a group with 1 μg / ml prednisolone (PSL) (Funakoshi). Seven days after the start of culture, the culture medium was centrifuged and only the culture supernatant was collected. The concentrations of IFNγ, TNF, IL-2, and IL-10 in the culture supernatant were measured using a Cytokine Beads Array kit (BD Biosciences) with a flow cytometer FACSCantoII (BD Biosciences). The relative cytokine concentrations under each culture condition were calculated, using the concentrations in the medium group culture medium as 100%, and the average values for four HAM patients were determined.
[0064] [Example 9: Induction of Apoptosis in Neuronal Cell Lines by HAM-PBMCs] Neuronal cell lines NB-1 or SK-N-AS were seeded in 6-well plates and cultured for 24 hours. Then, PBMCs from healthy individuals (HD) or HAM patients were added and co-cultured. 48 hours after the start of co-culture, the PBMCs added along with the culture medium were removed, and the neuronal cell lines were recovered after washing with PBS. Each recovered neuronal cell line was analyzed using the TUNEL method (MEBSTAIN Apoptosis TUNEL Kit Direct (MBL)) to specifically detect cells undergoing DNA fragmentation due to apoptosis. Figure 13 shows the analysis results. The X-axis in the histogram indicates the intensity of DNA fragmentation positivity. HAM-derived cells induced apoptosis more strongly in neuronal cell lines compared to HD-derived cells. Specifically, cell death was analyzed according to the following <Experimental Procedure>. <Experimental Procedure> Neuronal cell lines NB-1 and SK-N-AS were seeded in 6-well plates and cultured for 24 hours. Next, HD or HAM-PBMC was added (twice the number of seeded nerve cells) and cultured for 48 hours. After that, the cells were fixed with 4% paraformaldehyde and permeabilized with 70% ethanol. To perform DNA nick end labeling, the cells were suspended in 20 μL of TdT solution from the MEBSTAIN Apoptosis TUNEL Kit Direct (MBL) (TdT buffer II : TdT : FITC-dUTP = 18 : 1 : 1), reacted at 37°C for 60 minutes, and then FACS analysis was performed.
[0065] [Example 10: Inhibitory effect of RGMa antibody on apoptosis of neuronal cell lines induced by HTLV-1 Tax-expressing T cell lines] Neuronal cell line NB-1 was seeded in a 6-well plate and cultured for 24 hours. Then, unstimulated JPX9 (JPX9(-)) or JPX9 (JPX9(+CdCl2)) in which Tax expression was induced by adding 20 μM cadmium chloride for 24 hours was added and co-culture was performed. Furthermore, Normal Mouse IgG2b (MBL) or RGMa antibody (IBL) was added to the co-culture of NB-1 cells and JPX9 (+CdCl2) to a final concentration of 10 μg / ml. 48 hours after the start of co-culture, the JPX9 added along with the culture medium was removed, and the nerve cell lines were recovered after washing with PBS. Each recovered nerve cell line was analyzed using the TUNEL method (MEBSTAIN Apoptosis TUNEL Kit Direct (MBL)) to specifically detect cells undergoing DNA fragmentation due to apoptosis. Figure 14 shows the analysis results. The X-axis in the histogram indicates the intensity of DNA fragmentation positivity. Specifically, cell death analysis was performed according to the following <Experimental Procedure>. <Experimental Procedure> Nerve cell lines (NB-1) were seeded in a 6-well plate and cultured for 24 hours. Next, JPX9(-) or JPX9(+CdCl2) was added to NB-1 cells and co-cultured. The number of JPX9(-) or JPX9(+CdCl2) cells was twice the number of NB-1 cells seeded. For JPX9(+CdCl2), the cells were washed three times with 10 ml of medium to remove cadmium chloride before being added to the NB-1 cells. Subsequently, Normal Mouse IgG2b (MBL) or anti-RGMa antibody (IBL) was added to the co-culture of NB-1 cells and JPX9(+CdCl2) to a final concentration of 10 μg / ml, and the cells were cultured for 48 hours. After that, the cells were fixed with 4% paraformaldehyde, permeabilized with 70% ethanol, and stained with anti-CD45-V450 antibody.To perform DNA nick end labeling, cells were suspended in 20 μL of TdT solution from the MEBSTAIN Apoptosis TUNEL Kit Direct (MBL) (TdT buffer II : TdT : FITC-dUTP = 18 : 1 : 1), reacted at 37°C for 60 minutes, and then subjected to FACS analysis.
[0066] All content contained in publications, patent documents, and non-patent documents cited herein is incorporated herein by reference in its entirety.
Claims
1. A therapeutic or preventive agent for HTLV-1-associated myelopathy (HAM), comprising an RGMa inhibitor.
2. The therapeutic or preventive agent for HAM according to claim 1, wherein the RGMa inhibitor is an antibody that recognizes RGMa.
3. A method for treating HTLV-1-associated myelopathy (HAM), comprising administering a pharmacologically effective amount of an RGMa inhibitor to a patient with HAM in need thereof.
4. The method for treating HAM according to claim 3, wherein the RGMa inhibitor is an antibody that recognizes RGMa.
